We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+11.94%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$403M
AUM Growth
+$128M
Cap. Flow
+$111M
Cap. Flow %
27.45%
Top 10 Hldgs %
71.78%
Holding
84
New
19
Increased
11
Reduced
3
Closed
50

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$26.4M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$24.1M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$18.2M
5
NUAN
Nuance Communications, Inc.
NUAN
+$15.3M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$20.7M
2
VTRS icon
Viatris
VTRS
+$19.6M
3
LH icon
Labcorp
LH
+$11M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$10.3M
5
ZLAB icon
Zai Lab
ZLAB
+$8.42M

Sector Composition

Rank Sector Weight
1 Healthcare 71.82%
2 Technology 3.61%
3 Industrials 0.52%
4 Communication Services 0%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
26
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$2.5M 0.62%
+140,000
New +$2.42M
AERI
27
PUT
DELISTED
Aerie Pharmaceuticals
AERI
$2.5M 0.62%
+140,000
New +$2.42M
BGMS
28
Bio Green Med Solution Inc
BGMS
$5.41M
$2.09M 0.52%
+82
New +$2.31M
BLU
29
DELISTED
BELLUS Health Inc.
BLU
$1.46M 0.36%
+380,237
New +$1.44M
AVDL
30
DELISTED
Avadel Pharmaceuticals
AVDL
$1.45M 0.36%
+160,256
New +$1.3M
IMTX icon
31
Immatics
IMTX
$1.28B
$1.36M 0.34%
+121,743
New +$1.38M
AERI
32
DELISTED
Aerie Pharmaceuticals
AERI
$1.22M 0.3%
+68,472
New +$1.18M
EOLS icon
33
Evolus
EOLS
$403M
$1.05M 0.26%
+81,025
New +$747K
AMRX icon
34
Amneal Pharmaceuticals
AMRX
$5.9B
$939K 0.23%
+139,470
New +$773K
ABBV icon
35
AbbVie
ABBV
$431B
– –
-193,223
Closed -$20.7M
ALXO icon
36
ALX Oncology
ALXO
$265M
– –
-39,226
Closed -$3.38M
APLS
37
DELISTED
Apellis Pharmaceuticals
APLS
– –
-121,409
Closed -$6.95M
ARCT icon
38
Arcturus Therapeutics
ARCT
$177M
– –
-26,722
Closed -$1.16M
ARWR icon
39
Arrowhead Research
ARWR
$12.6B
– –
-56,003
Closed -$4.3M
BCE icon
40
BCE
BCE
$20.5B
– –
-5,825
Closed -$249K
BCRX icon
41
BioCryst Pharmaceuticals
BCRX
$2.29B
– –
-17,260
Closed -$129K
BPMC
42
DELISTED
Blueprint Medicines
BPMC
– –
-73,906
Closed -$8.29M
BTAI icon
43
BioXcel Therapeutics
BTAI
$26.6M
– –
-602
Closed -$445K
CHD icon
44
Church & Dwight Co
CHD
$24.4B
– –
-3,185
Closed -$278K
CL icon
45
Colgate-Palmolive
CL
$73.8B
– –
-4,343
Closed -$371K
CLRB icon
46
Cellectar Biosciences
CLRB
$20.5M
– –
-2,195
Closed -$1.37M
CLX icon
47
Clorox
CLX
$12.7B
– –
-1,234
Closed -$249K
COST icon
48
Costco
COST
$420B
– –
-841
Closed -$317K
CPB icon
49
Campbell Soup
CPB
$6.79B
– –
-4,432
Closed -$214K
CRDF icon
50
Cardiff Oncology
CRDF
$72.3M
– –
-157,403
Closed -$2.83M
1
2
3 4

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q1 2021 Portfolio in Review

As of Q1 2021, Tri Locum Partners held 84 positions worth $403M, up 46% from $275M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Tri Locum Partners deployed $111M of net new capital in Q1 2021, opening 19 new positions and adding to 11 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 293,426 shares worth $27M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 93% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Walgreens Boots Alliance, an estimated $2.05M trimmed.

  • Tri Locum Partners's largest Q1 2021 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 293,426 shares worth $27M.
  • Tri Locum Partners added most to Regeneron Pharmaceuticals in Q1 2021, an estimated $26.4M increase.
  • Tri Locum Partners's biggest Q1 2021 reduction was Walgreens Boots Alliance, cutting an estimated $2.05M.
  • Tri Locum Partners fully exited AbbVie in Q1 2021, selling an estimated $20.7M.
  • Tri Locum Partners's ten largest holdings make up 72% of its $403M portfolio in Q1 2021.
  • Tri Locum Partners opened 19 new positions and closed 50 in Q1 2021.
  • Tri Locum Partners's portfolio value rose 46% quarter-over-quarter to $403M.

Based on Tri Locum Partners's 13F filing for Q1 2021, filed 17 May 2021.